The abstract is read at the publisher; the summary is JClub's.
In eight patients with metastatic Merkel cell carcinoma progressing after prior systemic therapy, intratumoral T-VEC produced objective responses in 4 of 7 evaluable cases (57%).
- Why it matters: Because only about half of metastatic MCC patients respond to immune checkpoint inhibitors, clinicians need salvage approaches with acceptable toxicity and evidence of benefit.
- What they did: This retrospective series treated patients with intratumoral talimogene laherparepvec between 2017 and 2024, assessed response by investigator RECIST, recorded adverse events, and analyzed paired biopsies in two patients.
- The result: Responders had a median time to objective response of 9 months (range 1.2–14.2), with lasting responses up to 5.1 years in some; grade 3 adverse events occurred in 2 of 8, and biopsy correlates differed between a CR case and a non-responder.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.